Skip to Main Content

Paper Details

LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma.
Journal of Hepatology
4
2023
CCA, CCA cell lines, CCA cells, CCA patient-derived organoids, CCAs, FGFR2, FGFR2 fusion, FGFR2 fusions, Hippo, LCK, LCK proto-oncogene, NTRC 0652-0, Src family tyrosine kinase, YAP, Yes-associated protein, cholangiocarcinoma, fibroblast growth factor receptor 2, fibroblast growth factor receptor 2 (FGFR2)-rearrangements, patient, patient-derived models, patient-derived xenograft models, tumor, tyrosine, tyrosine kinase
Author NameAffiliation
Akhilesh PandeyMayo Clinic, USA Center for Individualized Medicine, USA Manipal Academy of Higher Education (MAHE)
  • 1 - 1

Datasets

Release 1.2